Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04676321
Other study ID # IRST 162.13
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date November 15, 2020

Study information

Verified date December 2020
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicenter, observational study involving a retrospective collection of data. A total of potential 16 key performance indicators (KPIs) had been developed from a panel of experts (clinicians, IT experts, etc..) to investigate the appropriateness of care in NSCLC patients, with a special focus on the use of immunotherapy. The eligible population and data will be gathered retrospectively using an algorithm. Administrative databases will be used as unique resource: to identify target population and to collect patient's data with which measure KPIs.


Description:

This is a multi-center, observational study involving retrospective collection of NSCLC patients information. All consecutive patients who had a newly diagnosis of NSCLC in 2017 from healthcare administrative database between January 2017 and December 2017, identified through the proposed algorithm, will be considered. All data needed for KPI calculation, even if they fall outside January-December 2017 period, will be collected. The end of data collection will be defined as patient death or 30 June 2018, whichever came first. A set of potential KPIs had been developed from a panel of experts (clinicians, IT experts etc..) to investigate the appropriateness of activities within NSCLC care pathway, with a special focus on the use of immunotherapy. The following KPIs will be measured to investigate the appropriateness of NSCLC patient care pathways, with a special focus on the use of immunotherapy: 1. Percentage of patients who performed biopsy within 7 days from the date of examination prescription; 2. Percentage of metastatic NSCLC patients at diagnosis; 3. Percentage of major surgical resections within the year of analysis; 4. Percentage of surgical patients on the total number of patients with exploratory thoracotomy in inpatient setting; 5. Percentage of patients undergoing neoadjuvant therapy ( CT or CT+RT within 6 months prior to the first major resection date; 6. 30-day mortality rate from major surgery; 7. Percentage of patients discussed in the multidisciplinary team (MDT) meeting at least once in the year of incidence; 8. Percentage of patients who performed imaging exams such as MRI, TC and PET within 7 days from MDT meeting; 9. Average and range of length of stay; 10. Average time between biopsy and the first administration of systematic anti-cancer drug; 11. Percentage of patients treated with immunotherapies; 12. Percentage of patients who underwent immunotherapy for more than 6 months after first dose; 13. Percentage of patients who underwent anti-cancer drug treatment in the last 30 days of life; 14. Percentage of patients who underwent the first administration of systematic anticancer drug within 30 days from discussed in MDT meeting; 15. Percentage of patients who underwent RT in the last 30 days of life ( excluded palliative treatments single fraction); 16. Percentage of patients who underwent at least one Integrated Home Care (IHC); 17. Percentage of patients who underwent at least one hospice care; The eligible population and data will be gathered retrospectively through an algorithm from administrative databases (Hospital discharge cards, pharmaceutical databases as FED and AFT - direct and territorial distribution, the regional register of mortality REM, the regional register of outpatient specialist medical procedure ASA, the integrated home care IHC, and SDHS-hospice). Administrative data will be used as unique resource to identify patients cohort and to measure KPIs along care pathway. An evaluation of the NSCLC patients selection algorithm will be performed on a sub-population using the electronic health record EHR as gold standard.


Recruitment information / eligibility

Status Completed
Enrollment 430
Est. completion date November 15, 2020
Est. primary completion date October 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients identified from hospital administrative databases of Emilia-Romagna region using a case selection algorithm for identifying Non small cell lung cancer Exclusion Criteria: - patients not residing in Emilia Romagna region (due to the difficulty in obtaining the medical data).

Study Design


Intervention

Other:
Patient pathway
Investigation on the appropriateness and quality of NSCLC care among participating sites

Locations

Country Name City State
Italy IRST Meldola Forlì-Cesena
Italy Policlinico of Modena Modena
Italy IRCCS Arcispedale S.Maria Nuova Reggio Emilia RE

Sponsors (3)

Lead Sponsor Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Azienda Ospedaliera Universitaria Policlinico, Azienda Unità Sanitaria Locale Reggio Emilia

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Key Performance indicators To measure a set of potential indicators (KPIs) derived from administrative database in order to investigate the appropriateness and quality of NSCLC care among participating sites. six months
Secondary Algorithm evaluatation The secondary outcome is to develop and evaluate an algorithm to identify the eligible population of the study from administrative databases against to a clinical database. Algorithm will be used to identify study eligible patients and measure KPIs from hospital administrative databases. two month
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1